ADGRL4

Across TCGA pan-cancer cohorts, ADGRL4 Mutation is linked to patient survival in 13 of 34 cancer types, making it a survival-associated ADGRL4 data layer compared with 21 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher ADGRL4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ADGRL4 expression acts as an unfavorable survival marker, although some lineages such as BLCA and UCEC show a favorable association.

ESCA, BLCA, and SCLC are the cancer types where ADGRL4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.164	0.702	.001	33	view →
BLCA	DFS	Median	All	1.000	0.321	.004	23	view →
SCLC	OS	Median	II,III,IV	0.068	0.668	<.001	21	view →
LGG	OS	Median	All	0.133	0.814	<.001	18	view →
UCEC	DFS	Median	All	0.927	0.614	.009	18	view →
CESC	DFS	Median	All	0.271	0.745	.001	12	view →
BRCA	OS	Median	II,III,IV	0.430	0.913	.002	12	view →
LIHC	OS	Median	All	0.577	0.781	.004	12	view →
KIRP	OS	Median	All	0.118	0.688	.007	6	view →
ACC	OS	Median	All	0.118	0.624	.038	6	view →
LUSC	DFS	Median	III,IV	0.079	0.751	.024	6	view →
GBM	OS	Median	All	0.075	0.416	.011	3	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 13 lineages.

ADGRL4–ESCA (OS)

Open the ESCA breakdown →